Research Article
Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer
Table 3
Univariate and multivariate analyses of OS and PFS in patients.
| Characteristic | OS | PFS | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | P | HR | 95% CI | P |
| Age (years) | ≤ 60 / > 60 | 0.753 | 0.163-3.377 | 0.711 | | | NI | 0.988 | 0.379-2.577 | 0.981 | | | NI | Gender | Female / Male | 8.535 | 0.994-72.563 | 0.055 | | | NI | 1.535 | 0.577-4.084 | 0.391 | | | NI | Tumor size (cm) | >4 / 2~4 / ≤ 2 | 1.405 | 0.405-4.876 | 0.592 | | | NI | 1.019 | 0.412-2.522 | 0.967 | | | NI | Tumor grade | Poor / Moderate / Well | 2.754 | 0.668-11.354 | 0.161 | | | NI | 0.910 | 0.391-2.117 | 0.827 | | | NI | Tumor site | Head / Body / Tail | 3.778 | 0.743-19.204 | 0.109 | | | NI | 0.848 | 0.393-1.830 | 0.674 | | | NI | WBC (109) | ≤ 10 / > 10 | 0.733 | 0.087-6.164 | 0.775 | | | NI | 1.019 | 0.412-2.522 | 0.967 | | | NI | HGB (g/L) | ≤ 120 / > 120 | 0.544 | 0.121-2.445 | 0.427 | | | NI | 1.202 | 0.377-4.280 | 0.777 | | | NI | PLT (109) | ≤ 300 / > 300 | 1.588 | 0.289-8.721 | 0.595 | | | NI | 0.477 | 0.107-2.116 | 0.330 | | | NI | ALT (U/L) | ≤ 40 / > 40 | 0.995 | 0.191-5.181 | 0.995 | | | NI | 0.409 | 0.117-1.431 | 0.162 | | | NI | AST (U/L) | ≤ 40 / > 40 | 0.033 | 0.000-67.662 | 0.382 | | | NI | 0.596 | 0.168-2.112 | 0.423 | | | NI | ALP (U/L) | ≤ 100 / > 100 | 0.832 | 0.185-3.742 | 0.811 | | | NI | 0.522 | 0.193-1.417 | 0.202 | | | NI | GGT (U/L) | ≤ 45 / > 45 | 1.404 | 0.310-6.365 | 0.660 | | | NI | 0.418 | 0.136-1.289 | 0.129 | | | NI | ALB (g/L) | ≤ 40 / > 40 | 0.572 | 0.066-4.939 | 0.611 | | | NI | 0.924 | 0.206-4.149 | 0.918 | | | NI | TBIL (umol/L) | ≤ 20.5 / > 20.5 | 0.033 | 0.000-67.662 | 0.382 | | | NI | 0.596 | 0.168-2.112 | 0.423 | | | NI | IBIL (umol/L) | ≤ 15 / > 15 | 0.040 | 0.000-95.774 | 0.530 | | | NI | 1.148 | 0.328-4.022 | 0.829 | | | NI | CRP (ng/L) | > 3 / ≤ 3 | 8.328 | 1.443-48.063 | 0.018 | 2.458 | 0.048-125.03 | 0.654 | 1.024 | 0.275-3.817 | 0.972 | | | NI | CEA (ng/mL) | ≤ 5 / > 5 | 0.999 | 0.193-5.161 | 0.999 | | | NI | 2.106 | 0.805-5.512 | 0.129 | | | NI | CA19-9 (U/ml) | ≤ 35 / > 35 | 0.865 | 0.165-4.554 | 0.868 | | | NI | 2.635 | 0.573-11.523 | 0.178 | | | NI | CD4+ T cell variation | Elevated/Non-elevated | 0.214 | 0.041-1.127 | 0.069 | | | NI | 0.920 | 0.343-2.470 | 0.869 | | | NI | CD8+ T cell variation | Elevated/Non-elevated | 0.056 | 0.006-0.490 | 0.009 | 0.039 | 0.002-0.780 | 0.034 | 0.354 | 0.122-1.026 | 0.046 | 0.418 | 0.138-0.954 | 0.049 | NK cell variation | Elevated/Non-elevated | 0.144 | 0.025-0.816 | 0.029 | 0.184 | 0.005-6.745 | 0.357 | 0.817 | 0.293-2.277 | 0.700 | | | NI | Treg cell variation | Decreased/Non-decreased | 0.165 | 0.033-0.820 | 0.028 | 1.056 | 0.026-43.365 | 0.977 | 0.452 | 0.166-1.228 | 0.119 | | | NI | IL-2 variation | Elevated/Non-elevated | 0.393 | 0.075-2.067 | 0.270 | | | NI | 0.408 | 0.116-1.438 | 0.163 | | | NI | IL-6 variation | Decreased/Non-decreased | 0.851 | 0.188-3.841 | 0.834 | | | NI | 0.645 | 0.190-2.187 | 0.482 | | | NI | IL-10 variation | Decreased/Non-decreased | 1.271 | 0.281-5.757 | 0.756 | | | NI | 1.262 | 0.396-4.020 | 0.694 | | | NI | C3 variation | Elevated/Non-elevated | 1.172 | 0.260-5.292 | 0.837 | | | NI | 1.386 | 0.419-4.584 | 0.592 | | | NI | C4 variation | Elevated/Non-elevated | 1.201 | 0.241-5.974 | 0.823 | | | NI | 1.458 | 0.434-4.893 | 0.542 | | | NI | IgG variation | Elevated/Non-elevated | 4.012 | 0.411-39.156 | 0.232 | | | NI | 1.459 | 0.237-8.985 | 0.684 | | | NI | NLR | > 1.47 / ≤ 1.47 | 5.967 | 0.680-52.400 | 0.107 | | | NI | 3.185 | 1.068-13.621 | 0.039 | 3.425 | 1.002 - 12.616 | 0.046 | PLR | > 165.29 / ≤ 165.29 | 3.752 | 0.738-19.073 | 0.111 | | | NI | 1.517 | 0.552-4.171 | 0.419 | | | NI | PI | 2 / 1 / 0 | 3.864 | 0.861-17.333 | 0.078 | | | NI | 1.292 | 0.439-3.804 | 0.642 | | | NI | mGPS | 2 / 1 / 0 | 3.264 | 1.266-8.413 | 0.014 | 4.285 | 0.355-51.673 | 0.252 | 0.921 | 0.284-2.987 | 0.891 | | | NI |
|
|
OS, overall survival; PFS, progression-free survival; NI, not included; Other abbreviations as in Table 1 |